Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Chronic Lymphocytic Leukemia|Mantle Cell Lymphoma|Acute Lymphoblastic Leukemia|Diffuse Large B Cell Lymphoma|Triple Negative Breast Cancer Malignancies
Interventions: DRUG: Fludarabine|DRUG: Cyclophosphamide|BIOLOGICAL: PRGN-3007
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Collaborators: Precigen, Inc